ArticleOncology letters2025
Preoperative C-reactive protein-albumin-lymphocyte index predicts survival outcomes in patients with stage I-III colorectal cancer: A retrospective cohort study.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic Value of Pretreatment C-Reactive-Protein-Albumin-Lymphocyte Index in Colorectal Cancer: Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Deciphering the potential of the C-reactive protein-albumin-lymphocyte index as a prognostic biomarker in malignancy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Clinical significance of the C-reactive protein-albumin-lymphocyte index in older patients with colorectal cancer.Surgery today · 2026Article
- The CALLY index as a predictive biomarker for the prognosis and treatment outcomes of colorectal cancer.Surgery today · 2026Article
- Nutritional prehabilitation strategies in abdominal surgery.Current opinion in clinical nutrition and metabolic care · 2026Review
- Article
- Prognostic Factors and Biomarker Performance in Patients with Colorectal Cancer Receiving Reduced-Dose 5-Fluorouracil Therapy: A Retrospective Cohort Analysis.Journal of clinical medicine · 2025Article
- CALLY index predicts survival and surgical outcomes in colorectal cancer.Frontiers in nutrition · 2025Article
- Prognostic value of the C-reactive protein-albumin-lymphocyte index versus traditional inflammatory markers after radical resection of colorectal cancer: a retrospective cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide. The present study aimed to investigate the value of the preoperative C-reactive protein-albumin-lymphocyte (CALLY) index in predicting recurrence-free survival (RFS) and overall survival (OS) rates in patients with stage I-III CRC. A retrospective analysis was conducted on 255 patients with stage I-III CRC who underwent radical resection. The optimal cutoff value of the CALLY index was determined by receiver operating characteristic curve analysis, and patients were stratified into high- and low-CALLY groups accordingly to assess its prognostic value for RFS and OS. The CALLY index had an area under the curve of 0.739 for predicting CRC prognosis. With a cutoff value of 6.790, patients in the high-CALLY group exhibited significantly better RFS and OS rates compared with those in the low-CALLY group. Multivariate Cox regression analysis confirmed CALLY as an independent prognostic factor. In conclusion, the preoperative CALLY index is an effective prognostic biomarker for predicting RFS and OS rates in patients with stage I-III CRC, demonstrating potential clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.